Visiting Professor in the Division of Surgery within the Department of Surgery and Cancer, Imperial College London, Pat Price is an academic clinical oncologist specialising in PET based molecular imaging, advanced radiotherapy techniques and translational research in oncology.
She pioneered the use of PET molecular imaging for micro-dosing pharmacokinetic and pharmacokinetic studies of new cancer agents and has one of the best insights into the potential of the application of this technology for oncology drug development. Through the PET Research Advisory Company www.the-pra.co.uk, she provides advice to organisations on current and projected future investments in PET.
In collaboration with the University of California, Davis, Pat Price has advised on the projected oncology research applications of the World’s first Total Body PET Scanner-EXPLORER Total-body imaging: Transforming the role of positron emission tomography. As of April 2018, this 2meters long scanner, which has been constructed by the United Imaging Healthcare company in China, is undergoing physical testing. Initial patient studies planned for later in 2018 are to be undertaken within paradigms defined by Prof Price. She is also actively engaged in developing the case for establishing a multi-disciplinary, international Total Body PET Scanner clinical research facility in the UK, based at Imperial College on the Hammersmith Hospital Campus.
Pat Price established the European Organization for the Research and Treatment of Cancer (EORTC) Functional Imaging group, developing strategic links between oncologists and imagers and guidelines for PET in clinical trials. She has networked research collaborations with leading academic cancer researchers and service deliverers in the UK and has advised in Europe, the USA and pharma. She has raised more than £20M in research funding, co-founded the Wolfson Molecular Imaging Centre with Prof Terry Jones at the University of Manchester and has also trained 22 clinical research fellows in experimental medicine to research degree level (including 8 international awards).
She established the Academic Department of Radiation Oncology at the Christie Hospital, University of Manchester. In 2005 she established the UK Academic Clinical Oncology and Radiobiology Research Network (ACORRN). This was re-launched in 2010 as the charity Action Radiotherapy www.actionradiotherapy.org. It is the UK's only charity dedicated to improving radiotherapy treatment. She is Chair of the trustees and the charity provides the secretariat for the UK government APPG on radiotherapy.
Professor Price is the co-editor of the standard UK oncology textbook 'Treatment of Cancer', now in its 6th edition. She was President of the British Oncological Association from 2002 to 2004 and was a member of the 2008 UK Research Assessment Exercise oncology subcommittee.
A recognized opinion leader in PET based molecular imaging in cancer and advanced radiotherapy, she was profiled in Cancer World: Pat Price: asking the right questions.
Professor Price has over 380 scientific publications and an H index of 50.
et al., 2019, First Human Imaging Studies with the EXPLORER Total-Body PET Scanner, Journal of Nuclear Medicine, Vol:60, ISSN:0161-5505, Pages:299-303
et al., 2018, Evaluation of CyberKnife ® fiducial tracking limitations to assist targeting accuracy: A phantom study with fiducial displacement, Cureus, Vol:10, ISSN:2168-8184
et al., 2018, Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity, Radiation Oncology, Vol:13, ISSN:1748-717X
et al., 2018, CyberKnife radiosurgery of skull-base tumors: A UK center experience, Cureus, Vol:10, ISSN:2168-8184
et al., 2017, An effective deep-inspiration breath-hold radiotherapy technique for left-breast cancer: impact of post-mastectomy treatment, nodal coverage, and dose schedule on organs at risk, Breast Cancer-targets and Therapy, Vol:9, ISSN:1179-1314, Pages:437-446